文献速递妇科

恩扎卢胺治疗雄激素受体阳性复发高级别和低级别浆液性卵巢癌的II期研究

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-11-08

这项单中心II期研究纳入59例既往接受1-3线化疗的雄激素受体阳性复发卵巢癌患者,每日口服恩扎卢胺160 mg至疾病进展或停药。主要终点6个月无进展生存率为22%,总体缓解率为1.7%,3级毒性见于6例患者。恩扎卢胺耐受性良好,可能成为部分患者的潜在治疗选择。

要点

  • 雄激素受体阳性复发卵巢癌患者每日口服恩扎卢胺160 mg,6个月无进展生存率为22%。
  • 总体缓解率仅1.7%,高级别浆液性癌6个月无进展生存率19.8%,低级别为38.5%。
  • 3级毒性见于6例患者,其中1例3级皮疹被视为剂量限制性毒性。

核心结论

  • 研究达到主要终点,6个月无进展生存率为22%(n=13),但总体缓解率低。
  • 恩扎卢胺耐受性良好,可能成为部分患者的潜在治疗选择。

研究设计与样本

  • 单中心II期研究,纳入雄激素受体阳性、可测量病灶、既往接受1-3线化疗的复发卵巢癌患者。
  • 2013年11月至2018年7月筛查患者,共59例(45例高级别浆液性癌、14例低级别浆液性癌)同意入组治疗。
  • 入组患者每日口服恩扎卢胺160 mg,直至疾病进展或治疗终止。
  • 不良事件按CTCAE v4.0分级,共同主要终点为6个月无进展生存率和按RECIST 1.1标准的总体缓解率。

主要发现

  • 共1例确认的部分缓解和1例未确认的部分缓解,总体缓解率为1.7%(90%CI:0.2-100%)。
  • 总体6个月无进展生存率(二分类)为22%(90%CI:15.1-100%)。
  • 6个月无进展生存率(时间至事件)在高级别浆液性癌患者为19.8%(90%CI:12.7-100%),在低级别浆液性癌患者为38.5%(90%CI:21.7%-100%)。
  • 3级毒性发生于6例患者,其中1例3级皮疹被视为剂量限制性毒性。
  • 1例患者在治疗42天后死于心脏骤停,判定与试验药物无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We sought to determine the safety and efficacy of the oral androgen receptor antagonist enzalutamide in patients with previously treated, recurrent, AR-positive (AR+) ovarian cancer. METHODS: This was a single-institution phase II study of patients with AR+ ovarian cancer with measurable disease with 1-3 prior lines of chemotherapy; patients were screened for enrollment from 11/2013-7/2018. Following consent, archival tissue was evaluated for AR+. Enrolled patients received daily enzalutamide 160 mg until progression of disease or treatment discontinuation. Adverse events were graded by CTCAE v4.0. Co-primary endpoints were 6-month progression-free survival (PFS6) and overall response rate (ORR) by RECIST 1.1 criteria. RESULTS: During the study period, 160 patients were screened and 59 (45 high-grade serous [HGS] and 14 low-grade serous [LGS]) consented to treatment on study. There was 1 confirmed and 1 unconfirmed partial response. The ORR was 1.7% (90% CI: 0.2-100%). The overall PFS6 rate (as binary) was 22% (90% CI: 15.1-100%). The 6-month PFS rate (as time to event) was 19.8% for HGS patients (90% CI: 12.7-100%) and 38.5% (90% CI: 21.7%-100%) for LGS patients. Grade 3 toxicities occurred in 6 patients (one toxicity (Grade 3 rash) was considered a dose-limiting toxicity). One patient died of cardiac arrest after 42 days on treatment of a cardiac arrest not attributed to study drug. CONCLUSIONS: The study met its primary endpoint, with a PFS6 rate of 22% (n = 13); however, the overall response rate was low. Enzalutamide was well tolerated and may be a potential treatment option in select patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Manning-Geist BL, Gordhandas SB, Giri DD, et al. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecol Oncol. 2021. PMID: 34763937. doi:10.1016/j.ygyno.2021.10.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。